Biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

Biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

After a stormy winter, biotech’s IPO hopes hang on a billion-dollar Alzheimer’s company

By DAMIAN GARDE @damiangarde

FEBRUARY 6, 2019

Coming up in the next few days

Alector, a South San Francisco company trying to treat Alzheimer’s disease with an unconventional approach reliant on the immune system, is expected to price its initial public offering sometime this week. My STAT colleague Damian Garde has a smart look at what Alector’s offering could say about the market’s appetite for biotech this year.

Another IPO to watch is from San Diego-based Gossamer Bio, which is working on treatments for inflammatory disease. Gossamer is expected to price its offering at the end of this week, after it considered going public during the government shutdown.